According to filings with the U.S. Securities and Exchange Commission, ArriVent Biopharma is raising $145,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Zhengbin Yao played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ArriVent Biopharma
As industry-leaders with proven track records of drug development and bringing important medicines to market, our team has the expertise needed to identify unique opportunities that bridge global biopharma innovations to the U.S., EU and beyond. We have established a deep, global network of biotechs and big Pharmas, providing us with access to unique and best-in-class drug candidates at various development stages, including those coming from the booming life sciences industry in China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, we aim to globalize medicines for patients with a broad range of diseases, with an initial focus in oncology. When identifying potential candidates, our focus is on compounds that have been validated through rigorous discovery and development processes, potentially mitigating risk while maintaining cost efficiency. We are proud to be working with the best and brightest minds in the field committed to maximizing patient benefit and have attracted top-tier investors, providing the necessary resources to help us realize our mission of accelerating the global development of innovative biopharma products.

To learn more about ArriVent Biopharma, visit http://arrivent.com/

Contact:
Zhengbin Yao, President and Chief Executive Officer
240-780-6356
https://www.linkedin.com/in/zhengbin-bing-yao-4340b96/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved